PeptiDream Inc
TSE:4587

Watchlist Manager
PeptiDream Inc Logo
PeptiDream Inc
TSE:4587
Watchlist
Price: 2 551 JPY -0.74%
Market Cap: 331.7B JPY
Have any thoughts about
PeptiDream Inc?
Write Note

Gross Margin
PeptiDream Inc

74.4%
Current
67%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.4%
=
Gross Profit
35.5B
/
Revenue
47.8B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
JP
PeptiDream Inc
TSE:4587
330.6B JPY
74%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
35.8B EUR
89%
Country JP
Market Cap 330.6B JPY
Gross Margin
74%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.8B EUR
Gross Margin
89%
No Stocks Found

PeptiDream Inc
Glance View

Market Cap
330.6B JPY
Industry
Biotechnology

PeptiDream Inc., a biopharmaceutical powerhouse based in Japan, has carved out a formidable niche by leveraging its proprietary Peptide Discovery Platform System (PDPS) to revolutionize drug development. Founded in 2006 by a team of visionary scientists, the company has positioned itself at the cutting edge of peptide therapeutics. By using the PDPS, PeptiDream identifies and optimizes macrocyclic peptide candidates that have the potential to address a myriad of complex diseases with unmet medical needs. This platform enables the company to create highly specific peptide-based drugs that can modulate challenging targets previously deemed “undruggable” by conventional methods. For PeptiDream, innovation isn’t just a mission statement but an operational ethos that drives its strategic collaborations and partnerships across the pharmaceutical landscape. Revenue generation at PeptiDream is predominantly through multi-faceted strategic collaborations with leading global pharmaceutical companies. By partnering with industry titans, PeptiDream licenses access to its cutting-edge PDPS technology and collaborates on drug discovery and development projects. This collaborative approach allows the company to secure upfront payments, research funding, milestone payments, and potential royalties on the eventual sales of successfully commercialized drugs. By securing a steady stream of income through these partnerships, PeptiDream not only sustains its robust research and development initiatives but also fuels an innovation pipeline that positions it as a leader in the burgeoning field of peptide-based therapeutics.

Intrinsic Value
2 516.1 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.4%
=
Gross Profit
35.5B
/
Revenue
47.8B
What is the Gross Margin of PeptiDream Inc?

Based on PeptiDream Inc's most recent financial statements, the company has Gross Margin of 74.4%.